DC60683 · Updated 27 October 2026
Lipid-168
Instructions for Use
Before use
Check the supplied lot number, batch COA, approved SDS, quantity and retest date. Pure form: −20 °C, 1 year; In solvent: −80 °C, 6 months; −20 °C, 1 month. Sealed and protected from light.
For small quantities of viscous or oily lipid, volumetric transfer can reduce weighing losses. Confirm solvent compatibility and solubility before preparing a stock; calculated volumes do not establish solubility.
Stock-solution planning
Volume (mL) = mass (mg) × 1000 / [molecular weight × concentration (mM)].
| Mass | 10 mM | 20 mM |
|---|---|---|
| 10 mg | 1.0239 mL | 0.5120 mL |
| 25 mg | 2.5599 mL | 1.2799 mL |
| 50 mg | 5.1197 mL | 2.5599 mL |
| 100 mg | 10.2395 mL | 5.1197 mL |
Literature formulation reference
| Component | DC Chemicals product | Molecular weight | Molar ratio | Mass at 1 µmol total lipid (mg) |
|---|---|---|---|---|
| Lipid-168 | DC60683 | 976.611 | 50 | 0.488306 |
| Cholesterol | DCD-041 | 386.65 | 38.5 | 0.148860 |
| DSPC | DC57005 | 790.15 | 10 | 0.079015 |
| DMG-PEG2000 | DC40169 | 2507 | 1.5 | 0.037605 |
The 2024 preprint reports a 50:38.5:10:1.5 molar ratio, N/P 4.5, ABE mRNA:sgRNA 1:1 mass ratio and citrate pH 5. These preparation details have not been independently reverified against the subscription-only final Methods. Particle and biological results below use the final publication. Mass conversion uses molecular weight 976.611; DMG-PEG2000 uses the catalog convention 2507.
Read the complete study conditions, biological results, tolerability and figures →
References
- Xu S, Liang D, Wang Q, et al. In vivo genome editing of human haematopoietic stem cells for treatment of blood disorders using mRNA delivery. Nature Biomedical Engineering 10, 473–489 (2026); published online 12 August 2025. DOI: 10.1038/s41551-025-01480-y. Figures 4–6, Supplementary Tables 8–9 and Source Data.
- Original 2024 preprint: historical formulation record, distinct from the final publication.